E4F1 and ZNF148 are transcriptional activators of the −57A > C and wild-type TERT promoter
Genome Research · 2023
DOI: 10.1101/gr.277724.123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genome Research, 2023. Verfasst von Boon Haow Chua und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Science Institute of Singapore, National University of Singapore, 117599 Singapore. Hauptthemen laut MEDLINE: Telomerase, Promoter Regions, Genetic, Transcription Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation Singapore, Singapore Ministry of Education, NUSMed.
Abstract (Originalsprache)
Point mutations within the TERT promoter are the most recurrent somatic noncoding mutations identified across different cancer types, including glioblastoma, melanoma, hepatocellular carcinoma, and bladder cancer. They are most abundant at −146C > T and −124C > T, and rarer at −57A > C, with the latter originally described as a familial case, but subsequently shown also to occur somatically. All three mutations create de novo E26-specific (ETS) binding sites and result in activation of the TERT gene, allowing cancer cells to achieve replicative immortality. Here, we used a systematic proteomics screen to identify transcription factors preferentially binding to the −146C > T, −124C > T, and −57A > C mutations. Although we confirmed binding of multiple ETS factors to the mutant −146C > T and −124C > T sequences, we identified E4F1 as a −57A > C–specific binder and ZNF148 as a TERT wild-type (WT) promoter binder that showed reduced interaction with the −124C > T allele. Both proteins are activating transcription factors that bind specifically to the −57A > C and WT (at position 124) TERT promoter sequence in corresponding cell lines, and up-regulate TERT transcription and telomerase activity. Our work describes new regulators of TERT gene expression with possible roles in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Science Institute of Singapore, National University of Singapore, 117599 Singapore.
- Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 117596 Singapore.
- Université Paris Cité, CNRS, Epigenetics and Cell Fate, F-75013 Paris, France.
- NUS Center for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, 117599 Singapore.
- Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma 74078, USA.
- Institute of Molecular Biology (IMB), 55128 Mainz, Germany.
ORCID-Profile: Sudhakar Jha, Falk Butter, Daniel G Tenen, Pierre-Antoine Defossez, Dennis Kappei
Förderung
- National Research Foundation Singapore
- Singapore Ministry of Education
- NUSMed
- Université de Paris-NUS
- Fondation ARC
Zitieren
APA
Chua, B. H., Zaal Anuar, N., Ferry, L., Domrane, C., Wittek, A., Mukundan, V. T., Jha, S., Butter, F., Tenen, D. G., Defossez, P. A., & Kappei, D. (2023). E4F1 and ZNF148 are transcriptional activators of the −57A > C and wild-type TERT promoter. Genome Research. https://doi.org/10.1101/gr.277724.123
Vancouver
Chua BH, Zaal Anuar N, Ferry L, Domrane C, Wittek A, Mukundan VT, et al. E4F1 and ZNF148 are transcriptional activators of the −57A > C and wild-type TERT promoter. Genome Research. 2023. doi:10.1101/gr.277724.123
BibTeX
@article{Chua2023,
author = {Chua, Boon Haow and Zaal Anuar, Nurkaiyisah and Ferry, Laure and Domrane, Cecilia and Wittek, Anna and Mukundan, Vineeth T and Jha, Sudhakar and Butter, Falk and Tenen, Daniel G and Defossez, Pierre-Antoine and Kappei, Dennis},
title = {E4F1 and ZNF148 are transcriptional activators of the −57A > C and wild-type TERT promoter},
journal = {Genome Research},
year = {2023},
doi = {10.1101/gr.277724.123}
}
EUVIMED